|
|||||
|
|
||||||
Journal of Clinical Oncology, Vol 26, No 15 (May 20), 2008: pp. 2558-2561 © 2008 American Society of Clinical Oncology. DOI: 10.1200/JCO.2007.14.3933 Histologic Results of Para-Aortic Lymphadenectomy in Patients Treated for Stage IB2/II Cervical Cancer With Negative [18F]Fluorodeoxyglucose Positron Emission Tomography Scans in the Para-Aortic Area
From the Departments of Surgery, Nuclear Medicine, Statistics, Pathology, and Radiation Therapy, Institut Gustave Roussy, and University Paris Sud, Villejuif, France Corresponding author: Philippe Morice, MD, Service de Chirurgie, Institut Gustave Roussy and University Paris Sud, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France; e-mail: morice{at}igr.fr Purpose: Histologic results of complete para-aortic lymphadenectomy were studied in patients treated for stage IB2/II cervical carcinoma who had no para-aortic uptake on [18F]fluorodeoxyglucose positron emission tomography combined with integrated computed tomography (FDG-PET/CT). Patients and Methods: Patients were treated between 2004 and 2006 for stage IB2/II cervical cancer. Magnetic resonance imaging of the abdomen and pelvis and FDG-PET/CT were initially performed. Patients with no para-aortic abnormalities were treated with external pelvic radiation therapy and concomitant chemotherapy followed by utero-vaginal brachytherapy. Para-aortic lymphadenectomy was then performed. FDG-PET/CT images were reviewed by two nuclear medicine specialists. Results: Thirty-eight patients were studied. Three patients had histologically proven para-aortic involvement (metastatic nodes with capsular rupture in the para-aortic area), leading to a negative predictive value of 92% for para-aortic nodal involvement. Conclusion: In this study, three of 38 patients with no para-aortic uptake on [18F]FDG-PET/CT imaging had histologically proven para-aortic node involvement. PET/CT imaging without histologic examination of the para-aortic area used to determine radiation therapy fields in stage IB2/II cervical cancer would overlook 8% of patients with histologic para-aortic nodal involvement. Presented at the 39th Annual Meeting of the Society of Gynecologic Oncology, March 9-12, 2008, Tampa, FL. Authors disclosures of potential conflicts of interest and author contributions are found at the end of this article.
|
|
|||||||||||
|
Copyright © 2008 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
|